NEW YORK (GenomeWeb News) – Promega today announced that it has inked an alliance with Puracyp, under which the firms are combining their cell line and assay technologies in an offering to researchers.
The collaboration intends to provide all-inclusive kits for nuclear receptor activation, P450 metabolism, and cellular toxicity research in the drug development process. It combines Puracyp's nuclear receptor expressing cell lines with Promega's assay and detection technologies for bioluminescent reporters, cell viability, and P450 metabolism assays.